Leverage RWE to Advance Decision Making in Clinical Research, Regulatory Submissions, Payer Negotiations & Market Access
As the CMS introduces new guidance for RWD studies, the FDA announces a RWE Center to promote its use in regulatory decision-making, and RWD becomes more accessible, investment is pouring into RWE generation. It is evident RWE will play an increasingly pivotal role in the drug development lifecycle, but questions still remain for the experts optimizing and applying RWE.
The 13th IMPACCT Real-World Evidence Summit returned to Boston in October 2025, offering delegates the unique opportunity to consolidate, innovate and optimize their RWE strategy at all stages of the drug development lifecycle.
Attendees connected with 140+ industry pioneers from Kite Pharma, AbbVie, Alexion Pharmaceuticals, Biogen, and Boehringer Ingelheim, where they shared first-hand case studies in fortifying data quality, validating use of AI and predictive modeling in data analysis, leveraging RWE to support regulatory submissions and more.
2025 Expert Speaker Faculty:
Attending Companies Included